PT3189081T - Agentes de ligação a cd123 e seus usos - Google Patents

Agentes de ligação a cd123 e seus usos

Info

Publication number: PT3189081T
Authority: PT; Portugal
Prior art keywords: binding agents; binding; agents
Prior art date: 2014-09-05

Application number

PT157669730T

Other languages

English (en)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-05

Filing date

2015-09-03

Publication date

2020-05-25

2015-09-03 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2020-05-25 Publication of PT3189081T publication Critical patent/PT3189081T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

PT157669730T 2014-09-05 2015-09-03 Agentes de ligação a cd123 e seus usos PT3189081T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462046682P	2014-09-05	2014-09-05

Publications (1)

Publication Number	Publication Date
PT3189081T true PT3189081T (pt)	2020-05-25

Family

ID=54150667

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT157669730T PT3189081T (pt)	2014-09-05	2015-09-03	Agentes de ligação a cd123 e seus usos

Country Status (38)

Country	Link
US (1)	US9850310B2 (pt)
EP (2)	EP3189081B1 (pt)
JP (2)	JP6805130B2 (pt)
KR (1)	KR102540192B1 (pt)
CN (1)	CN107074956B (pt)
AR (1)	AR101765A1 (pt)
AU (1)	AU2015311931B2 (pt)
CA (1)	CA2959171C (pt)
CL (1)	CL2017000515A1 (pt)
CO (1)	CO2017002196A2 (pt)
CR (1)	CR20170079A (pt)
CY (1)	CY1122858T1 (pt)
DK (1)	DK3189081T3 (pt)
EA (1)	EA037647B1 (pt)
EC (1)	ECSP17020812A (pt)
ES (1)	ES2791249T3 (pt)
HR (1)	HRP20200745T1 (pt)
HU (1)	HUE048791T2 (pt)
IL (1)	IL250770B (pt)
JO (1)	JO3568B1 (pt)
LT (1)	LT3189081T (pt)
MA (2)	MA40609B1 (pt)
ME (1)	ME03724B (pt)
MX (1)	MX2017002891A (pt)
MY (1)	MY186337A (pt)
NI (1)	NI201700025A (pt)
PE (1)	PE20171556A1 (pt)
PH (1)	PH12017500472A1 (pt)
PL (1)	PL3189081T3 (pt)
PT (1)	PT3189081T (pt)
RS (1)	RS60305B1 (pt)
SG (1)	SG11201701599UA (pt)
SI (1)	SI3189081T1 (pt)
TW (1)	TWI693233B (pt)
UA (1)	UA120060C2 (pt)
UY (1)	UY36289A (pt)
WO (1)	WO2016036937A1 (pt)
ZA (1)	ZA201702369B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112012026766B1 (pt) *	2010-04-20	2021-11-03	Genmab A/S	Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
EP4039710A3 (en)	2015-01-23	2022-10-19	Sanofi	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
US10100118B2 (en)	2015-04-08	2018-10-16	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind CD123
CN107849148B (zh)	2015-05-21	2023-09-19	哈普恩治疗公司	三特异性结合蛋白质及使用方法
US10077313B2 (en)	2015-06-29	2018-09-18	Immunogen, Inc.	Anti-CD123 antibodies and conjugates and derivatives thereof
WO2017040344A2 (en)	2015-08-28	2017-03-09	Amunix Operating Inc.	Chimeric polypeptide assembly and methods of making and using the same
CR20180318A (es)	2015-12-14	2018-09-19	Macrogenics Inc	Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
BR112018073761A2 (pt)	2016-05-20	2019-02-26	Harpoon Therapeutics, Inc.	proteínas de ligação ao cd3 de fragmento variável de cadeia única
US10100106B2 (en)	2016-05-20	2018-10-16	Harpoon Therapeutics, Inc.	Single domain serum albumin binding protein
IL262996B2 (en)	2016-06-06	2024-03-01	Hoffmann La Roche	Fusion proteins for ophthalmology with increased grip in the eye
MX2018014950A (es)	2016-06-07	2019-04-25	Macrogenics Inc	Terapia de combinacion.
TWI790206B (zh) *	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) *	2016-07-20	2022-10-21	比利時商健生藥品公司	抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) *	2016-09-19	2018-03-27	上海吉倍生物技术有限公司	高亲和力的抗cd123抗体及其应用
BR112019005333A2 (pt) *	2016-09-21	2019-06-11	Aptevo Research And Development Llc	proteínas de ligação a cd123 e composições e métodos relacionados
MX2019006045A (es)	2016-11-23	2019-11-11	Harpoon Therapeutics Inc	Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2019006043A (es)	2016-11-23	2019-09-26	Harpoon Therapeutics Inc	Proteína de unión de antígeno prostático específico de membrana.
CN110520158A (zh) *	2017-02-06	2019-11-29	丹娜法伯癌症研究所公司	用于增强抗体介导的受体信号传导的组合物和方法
JP7132232B2 (ja)	2017-02-24	2022-09-06	マクロジェニクス，インコーポレーテッド	Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
EP3589662A4 (en)	2017-02-28	2020-12-30	Harpoon Therapeutics, Inc.	INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
EP3596130A4 (en) *	2017-03-14	2020-12-30	Sunshine Lake Pharma Co., Ltd.	DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN
US10730954B2 (en)	2017-05-12	2020-08-04	Harpoon Therapeutics, Inc.	MSLN targeting trispecific proteins and methods of use
EP3621994A4 (en)	2017-05-12	2020-12-30	Harpoon Therapeutics, Inc.	MESOTHELINE BINDING PROTEINS
EP3668898B1 (en)	2017-08-14	2023-07-05	MorphoSys AG	Humanized antibodies for cd3
WO2019050521A1 (en) *	2017-09-07	2019-03-14	Macrogenics, Inc.	DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
MX2020003915A (es)	2017-10-13	2020-10-08	Harpoon Therapeutics Inc	Proteinas trispecificas y metodos de uso.
JP7066837B2 (ja)	2017-10-13	2022-05-13	ハープーンセラピューティクス，インク．	Ｂ細胞成熟抗原結合タンパク質
AU2018357221A1 (en) *	2017-10-27	2020-04-30	Pfizer Inc.	Antibodies and antibody-drug conjugates specific for CD123 and uses thereof
US11795226B2 (en)	2017-12-12	2023-10-24	Macrogenics, Inc.	Bispecific CD16-binding molecules and their use in the treatment of disease
US11685781B2 (en)	2018-02-15	2023-06-27	Macrogenics, Inc.	Variant CD3-binding domains and their use in combination therapies for the treatment of disease
AU2019235523A1 (en) *	2018-03-14	2020-10-29	Novimmune Sa	Anti-CD3 epsilon antibodies and methods of use thereof
KR20210011002A (ko) *	2018-05-16	2021-01-29	얀센 바이오테크 인코포레이티드	암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법
SG11202011633SA (en)	2018-05-24	2020-12-30	Janssen Biotech Inc	Psma binding agents and uses thereof
JOP20190116A1 (ar) *	2018-05-24	2019-11-24	Janssen Biotech Inc	الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CR20200564A (es)	2018-05-24	2021-06-21	Janssen Biotech Inc	Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
US10815311B2 (en)	2018-09-25	2020-10-27	Harpoon Therapeutics, Inc.	DLL3 binding proteins and methods of use
EP3868782A1 (en) *	2018-10-17	2021-08-25	Good T Cells, Inc.	Binding molecule specific to lrig-1 protein, and use thereof
MX2021010857A (es)	2019-03-11	2021-12-15	Janssen Biotech Inc	Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
US11591395B2 (en)	2019-04-19	2023-02-28	Janssen Biotech, Inc.	Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
CN113912695B (zh) *	2019-07-24	2023-05-30	暨南大学	靶向cd133的结合蛋白及应用
GB201912681D0 (en)	2019-09-04	2019-10-16	Eth Zuerich	Bispecific binding agent that binds to cd117/c-kit and cd3
IL295448A (en)	2020-02-21	2022-10-01	Harpoon Therapeutics Inc	flt3 binding proteins and methods of use
KR20230051617A (ko)	2020-03-13	2023-04-18	얀센 바이오테크 인코포레이티드	Siglec-3/cd33을 결합시키기 위한 물질 및 방법
MX2022014426A (es)	2020-05-19	2023-04-21	Janssen Biotech Inc	Composiciones que comprenden una terapéutica de redirección de células t y un inhibidor de la ruta de adhesión de vla-4.
AU2021364387A1 (en) *	2020-10-23	2023-06-15	Asher Biotherapeutics, Inc.	Fusions with cd8 antigen binding molecules for modulating immune cell function
KR20230127306A (ko)	2020-12-31	2023-08-31	사노피	NKp46 및 CD123에 결합하는 다기능성 자연살해(NK)세포 관여자
MX2023008949A (es)	2021-01-28	2023-10-23	Regeneron Pharma	Composiciones y metodos para tratar el sindrome de liberacion de citocinas.
MX2023013791A (es)	2021-05-18	2024-02-13	Janssen Biotech Inc	Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44.
EP4340866A1 (en)	2021-05-19	2024-03-27	Asher Biotherapeutics, Inc.	Il-21 polypeptides and targeted constructs
IL310700A (en) *	2021-08-09	2024-04-01	Merck Patent Gmbh	Proteins that uncouple cell-mediated tumor cytotoxicity from proinflammatory cytokine release
CN118574646A (zh) *	2022-01-19	2024-08-30	上海优替济生生物医药有限公司	环状rna及其用途
AU2023254191A1 (en)	2022-04-11	2024-10-17	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing
WO2024173830A2 (en)	2023-02-17	2024-08-22	Regeneron Pharmaceuticals, Inc.	Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1997024373A1 (en)	1995-12-29	1997-07-10	Medvet Science Pty. Limited	Monoclonal antibody antagonists to haemopoietic growth factors
US6670127B2 (en)	1997-09-16	2003-12-30	Egea Biosciences, Inc.	Method for assembly of a polynucleotide encoding a target polypeptide
PT1538206E (pt)	1997-09-16	2010-04-12	Centocor Ortho Biotech Inc	Método para a síntese química e construção completa de genes e genomas
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP1789446A2 (en)	2004-09-02	2007-05-30	Genentech, Inc.	Heteromultimeric molecules
US10011858B2 (en)	2005-03-31	2018-07-03	Chugai Seiyaku Kabushiki Kaisha	Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de)	2005-06-22	2006-12-28	SUNJÜT Deutschland GmbH	Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US10155816B2 (en)	2005-11-28	2018-12-18	Genmab A/S	Recombinant monovalent antibodies and methods for production thereof
WO2007147901A1 (en)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production of bispecific antibodies
JP2011507519A (ja)	2007-12-19	2011-03-10	セントコア・オーソ・バイオテツク・インコーポレーテツド	ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
CA2759233C (en)	2009-04-27	2019-07-16	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
ES2550639T3 (es) *	2009-04-27	2015-11-11	Kyowa Hakko Kirin Co., Ltd.	Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
CN102597775A (zh) *	2009-09-25	2012-07-18	佐马技术有限公司	筛选方法
BR112012026766B1 (pt)	2010-04-20	2021-11-03	Genmab A/S	Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
NZ604510A (en) *	2010-08-17	2013-10-25	Csl Ltd	Dilutable biocidal compositions and methods of use
CN108341868B (zh)	2010-11-05	2022-06-07	酵活有限公司	在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN104080811B (zh)	2011-11-04	2019-09-27	酵活有限公司	在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9745381B2 (en) *	2012-05-18	2017-08-29	Scott & White Healthcare (Swh)	Bispecific scFv immunofusion (BIf)

2015
- 2015-09-03 MA MA40609A patent/MA40609B1/fr unknown
- 2015-09-03 AU AU2015311931A patent/AU2015311931B2/en active Active
- 2015-09-03 PT PT157669730T patent/PT3189081T/pt unknown
- 2015-09-03 WO PCT/US2015/048316 patent/WO2016036937A1/en active Application Filing
- 2015-09-03 EP EP15766973.0A patent/EP3189081B1/en active Active
- 2015-09-03 MY MYPI2017700741A patent/MY186337A/en unknown
- 2015-09-03 CA CA2959171A patent/CA2959171C/en active Active
- 2015-09-03 ME MEP-2020-93A patent/ME03724B/me unknown
- 2015-09-03 LT LTEP15766973.0T patent/LT3189081T/lt unknown
- 2015-09-03 CN CN201580060369.4A patent/CN107074956B/zh active Active
- 2015-09-03 PL PL15766973T patent/PL3189081T3/pl unknown
- 2015-09-03 SI SI201531192T patent/SI3189081T1/sl unknown
- 2015-09-03 MA MA053145A patent/MA53145A/fr unknown
- 2015-09-03 UA UAA201703200A patent/UA120060C2/uk unknown
- 2015-09-03 MX MX2017002891A patent/MX2017002891A/es unknown
- 2015-09-03 JP JP2017512813A patent/JP6805130B2/ja active Active
- 2015-09-03 TW TW104129109A patent/TWI693233B/zh not_active IP Right Cessation
- 2015-09-03 EA EA201790530A patent/EA037647B1/ru unknown
- 2015-09-03 RS RS20200573A patent/RS60305B1/sr unknown
- 2015-09-03 US US14/844,194 patent/US9850310B2/en active Active
- 2015-09-03 SG SG11201701599UA patent/SG11201701599UA/en unknown
- 2015-09-03 JO JOP/2015/0216A patent/JO3568B1/ar active
- 2015-09-03 EP EP20157898.6A patent/EP3722315A1/en not_active Withdrawn
- 2015-09-03 KR KR1020177008815A patent/KR102540192B1/ko active IP Right Grant
- 2015-09-03 ES ES15766973T patent/ES2791249T3/es active Active
- 2015-09-03 DK DK15766973.0T patent/DK3189081T3/da active
- 2015-09-03 HU HUE15766973A patent/HUE048791T2/hu unknown
- 2015-09-03 PE PE2017000397A patent/PE20171556A1/es unknown
- 2015-09-03 CR CR20170079A patent/CR20170079A/es unknown
- 2015-09-04 UY UY0001036289A patent/UY36289A/es not_active Application Discontinuation
- 2015-09-04 AR ARP150102836A patent/AR101765A1/es unknown
2017
- 2017-02-26 IL IL250770A patent/IL250770B/en active IP Right Grant
- 2017-03-03 CL CL2017000515A patent/CL2017000515A1/es unknown
- 2017-03-03 NI NI201700025A patent/NI201700025A/es unknown
- 2017-03-06 CO CONC2017/0002196A patent/CO2017002196A2/es unknown
- 2017-03-13 PH PH12017500472A patent/PH12017500472A1/en unknown
- 2017-04-04 ZA ZA2017/02369A patent/ZA201702369B/en unknown
- 2017-04-05 EC ECIEPI201720812A patent/ECSP17020812A/es unknown
2020
- 2020-05-08 HR HRP20200745TT patent/HRP20200745T1/hr unknown
- 2020-05-18 CY CY20201100453T patent/CY1122858T1/el unknown
- 2020-12-02 JP JP2020199977A patent/JP2021050216A/ja not_active Ceased

Also Published As

Publication number	Publication date
EA037647B1 (ru)	2021-04-27
JP2021050216A (ja)	2021-04-01
CL2017000515A1 (es)	2018-03-16
CY1122858T1 (el)	2021-05-05
EA201790530A1 (ru)	2018-03-30
ZA201702369B (en)	2018-12-19
ES2791249T3 (es)	2020-11-03
CR20170079A (es)	2017-04-27
SG11201701599UA (en)	2017-03-30
CO2017002196A2 (es)	2017-07-28
PL3189081T3 (pl)	2020-10-05
LT3189081T (lt)	2020-05-11
MA40609B1 (fr)	2020-05-29
CN107074956A (zh)	2017-08-18
US9850310B2 (en)	2017-12-26
UY36289A (es)	2016-04-01
EP3189081A1 (en)	2017-07-12
CA2959171C (en)	2023-11-14
RS60305B1 (sr)	2020-07-31
JO3568B1 (ar)	2020-07-05
EP3722315A1 (en)	2020-10-14
DK3189081T3 (da)	2020-05-04
TW201625687A (zh)	2016-07-16
SI3189081T1 (sl)	2020-07-31
KR20170049554A (ko)	2017-05-10
JP6805130B2 (ja)	2020-12-23
US20160068605A1 (en)	2016-03-10
MX2017002891A (es)	2017-10-11
JP2017529838A (ja)	2017-10-12
ME03724B (me)	2021-01-20
UA120060C2 (uk)	2019-09-25
TWI693233B (zh)	2020-05-11
WO2016036937A1 (en)	2016-03-10
ECSP17020812A (es)	2018-07-31
EP3189081B1 (en)	2020-02-19
BR112017004322A2 (pt)	2017-12-05
HUE048791T2 (hu)	2020-09-28
MA53145A (fr)	2021-05-19
CA2959171A1 (en)	2016-03-10
AR101765A1 (es)	2017-01-11
CN107074956B (zh)	2021-11-26
KR102540192B1 (ko)	2023-06-02
PE20171556A1 (es)	2017-10-27
PH12017500472A1 (en)	2017-07-31
HRP20200745T1 (hr)	2020-08-07
IL250770B (en)	2020-10-29
AU2015311931A1 (en)	2017-03-16
NI201700025A (es)	2017-06-22
IL250770A0 (en)	2017-04-30
AU2015311931B2 (en)	2020-09-03
MY186337A (en)	2021-07-13

Publication	Publication Date	Title
ZA201702369B (en)	2018-12-19	Cd123 binding agents and uses thereof
HK1255067A1 (zh)	2019-08-02	抗c10orf54抗體及其用途
HK1243440A1 (zh)	2018-07-13	抗白細胞介素-33抗體及其用途
ZA201605894B (en)	2019-07-31	Anti-egfrviii antibodies and uses thereof
HK1231471A1 (zh)	2017-12-22	-雜芳氧基-和芳氧基-喹啉- -甲酰胺及其用途
HUE044571T2 (hu)	2019-11-28	Módosított ciklopentapeptidek és alkalmazásaik
ZA201701663B (en)	2023-04-26	Anti-il-25 antibodies and uses thereof
GB201408091D0 (en)	2014-06-18	Methods and uses
EP3180027A4 (en)	2018-01-10	Rspo1 binding agents and uses thereof
GB201416073D0 (en)	2014-10-29	Methods and uses